pharmaceuticals-and-healthcare

United States Next Generation Cancer Diagnostics Market Report 2017


Published On : Feb 2017

Category : Cancer Diagnostics

No. of Pages : 120 pages

  • $3800
  • $7600

Please click below to avail discount on this report

Notes:
Sales, means the sales volume of Next Generation Cancer Diagnostics
Revenue, means the sales value of Next Generation Cancer Diagnostics

This report studies sales (consumption) of Next Generation Cancer Diagnostics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
Cepheid
Koninklijke Philips N.V
F. Hoffmann-La Roche Ltd
Qiagen
Novartis AG
Abbott
Thermo Fisher Scientific
Opko Health
Myriad Genetics
Agilent Technologies
GE Healthcare
PerkinElmer
Genomic Health
Illumina
Hologic
Almac Group
Janssen Global Services
Sysmex Corporation

Market Segment by States, covering
California
Texas
New York
Florida
Illinois
Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
Next Generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
Split by applications, this report focuses on sales, market share and growth rate of Next Generation Cancer Diagnostics in each application, can be divided into
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others

Cancer diagnostics involves various methods and techniques for diagnosing cancer in several stages. Many of the cancer types are primarily recognized either through screening or through the appearance of early signs and symptoms. However, these do not lead to a conclusive diagnosis which needs a pathologist to examine a tissue sample. Patients suspected with cancer go through several medical tests such as endoscopy, CT scans, X-rays, and blood tests. For instance, oncology is part of medicine that is relate to the diagnosis, treatment, and prevention of cancer. The growing number of private diagnostic centers is anticipated to bode well for the growth of the cancer diagnostics industry.

The research report specifies various aspects of the United states next generation cancer diagnostics market report 2017 market with transparent and clear picture of the current and future conditions of the market along with germane information regarding the market. It also puts focus on the developments and elements at play that are expected to impact the growth of the United states next generation cancer diagnostics market report 2017 market in the long run. The forecast period covered in the report has been thought of microscopically and the researchers have further penetrated into industrial and production chain of the concerned market. This is also expected to help in broadcasting accurate statistics and data on multiple aspects concerning to the United states next generation cancer diagnostics market report 2017 market. Such factors might include government policies in the global and regional strata, production and product flow structure, manufacturing capacity of the production unit, products sold, and revenue earned along with the profit margins being met.

The market study further provides a comprehensive examination of the regions mentioned in the report for the market for United states next generation cancer diagnostics market report 2017. For every mentioned region, the report articulates the progress of the market so far and the upcoming growth has also been mapped in the report. The market research report will also present an edifying overview of the competitive landscape of the United states next generation cancer diagnostics market report 2017 market with a compilation of inventions, activities, facts, figures, product portfolio, and strategies. Special focus has been put on occurring mergers and acquisitions along with upcoming agreements and developments of the influential market players. 

Table of Contents

United States Next Generation Cancer Diagnostics Market Report 2017
1 Next Generation Cancer Diagnostics Overview
1.1 Product Overview and Scope of Next Generation Cancer Diagnostics
1.2 Classification of Next Generation Cancer Diagnostics
1.2.1 Next Generation Sequencing
1.2.2 qPCR & Multiplexing
1.2.3 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
1.2.4 Protein Microarrays
1.2.5 DNA Microarrays
1.3 Application of Next Generation Cancer Diagnostics
1.3.1 Lung Cancer
1.3.2 Breast Cancer
1.3.3 Colorectal Cancer
1.3.4 Cervical Cancer
1.3.5 Others
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Next Generation Cancer Diagnostics (2012-2022)
1.4.1 United States Next Generation Cancer Diagnostics Sales and Growth Rate (2012-2022)
1.4.2 United States Next Generation Cancer Diagnostics Revenue and Growth Rate (2012-2022)

2 United States Next Generation Cancer Diagnostics Competition by Manufacturers
2.1 United States Next Generation Cancer Diagnostics Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Next Generation Cancer Diagnostics Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Next Generation Cancer Diagnostics Average Price by Manufactures (2015 and 2016)
2.4 Next Generation Cancer Diagnostics Market Competitive Situation and Trends
2.4.1 Next Generation Cancer Diagnostics Market Concentration Rate
2.4.2 Next Generation Cancer Diagnostics Market Share of Top 3 and Top 5 Manufacturers
2.4.3 Mergers & Acquisitions, Expansion

3 United States Next Generation Cancer Diagnostics Sales (Volume) and Revenue (Value) by States (2012-2017)
3.1 United States Next Generation Cancer Diagnostics Sales and Market Share by States (2012-2017)
3.2 United States Next Generation Cancer Diagnostics Revenue and Market Share by States (2012-2017)
3.3 United States Next Generation Cancer Diagnostics Price by States (2012-2017)

4 United States Next Generation Cancer Diagnostics Sales (Volume) and Revenue (Value) by Type (2012-2017)
4.1 United States Next Generation Cancer Diagnostics Sales and Market Share by Type (2012-2017)
4.2 United States Next Generation Cancer Diagnostics Revenue and Market Share by Type (2012-2017)
4.3 United States Next Generation Cancer Diagnostics Price by Type (2012-2017)
4.4 United States Next Generation Cancer Diagnostics Sales Growth Rate by Type (2012-2017)

5 United States Next Generation Cancer Diagnostics Sales (Volume) by Application (2012-2017)
5.1 United States Next Generation Cancer Diagnostics Sales and Market Share by Application (2012-2017)
5.2 United States Next Generation Cancer Diagnostics Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 United States Next Generation Cancer Diagnostics Manufacturers Profiles/Analysis
6.1 Cepheid
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.1.2.1 Next Generation Sequencing
6.1.2.2 qPCR & Multiplexing
6.1.3 Cepheid Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Koninklijke Philips N.V
6.2.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.2.2.1 Next Generation Sequencing
6.2.2.2 qPCR & Multiplexing
6.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 F. Hoffmann-La Roche Ltd
6.3.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.3.2.1 Next Generation Sequencing
6.3.2.2 qPCR & Multiplexing
6.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Qiagen
6.4.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.4.2.1 Next Generation Sequencing
6.4.2.2 qPCR & Multiplexing
6.4.3 Qiagen Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Novartis AG
6.5.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.5.2.1 Next Generation Sequencing
6.5.2.2 qPCR & Multiplexing
6.5.3 Novartis AG Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Abbott
6.6.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.6.2.1 Next Generation Sequencing
6.6.2.2 qPCR & Multiplexing
6.6.3 Abbott Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Thermo Fisher Scientific
6.7.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.7.2.1 Next Generation Sequencing
6.7.2.2 qPCR & Multiplexing
6.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Opko Health
6.8.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.8.2.1 Next Generation Sequencing
6.8.2.2 qPCR & Multiplexing
6.8.3 Opko Health Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Myriad Genetics
6.9.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.9.2.1 Next Generation Sequencing
6.9.2.2 qPCR & Multiplexing
6.9.3 Myriad Genetics Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Agilent Technologies
6.10.2 Next Generation Cancer Diagnostics Product Type, Application and Specification
6.10.2.1 Next Generation Sequencing
6.10.2.2 qPCR & Multiplexing
6.10.3 Agilent Technologies Next Generation Cancer Diagnostics Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 GE Healthcare
6.12 PerkinElmer
6.13 Genomic Health
6.14 Illumina
6.15 Hologic
6.16 Almac Group
6.17 Janssen Global Services
6.18 Sysmex Corporation

7 Next Generation Cancer Diagnostics Manufacturing Cost Analysis
7.1 Next Generation Cancer Diagnostics Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Next Generation Cancer Diagnostics

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Next Generation Cancer Diagnostics Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Next Generation Cancer Diagnostics Major Manufacturers in 2015
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Next Generation Cancer Diagnostics Market Forecast (2017-2022)
11.1 United States Next Generation Cancer Diagnostics Sales, Revenue Forecast (2017-2022)
11.2 United States Next Generation Cancer Diagnostics Sales Forecast by Type (2017-2022)
11.3 United States Next Generation Cancer Diagnostics Sales Forecast by Application (2017-2022)
11.4 Next Generation Cancer Diagnostics Price Forecast (2017-2022)

12 Research Findings and Conclusion

13 Appendix
Methodology
Analyst Introduction
Data Source

Request a Sample Copy

  • * :
  • * :
  • * :
  • * :
  • * :
  • :
  • * :
  • * indicates required field.

LATEST NEWS


Back To Top